Back to Authors

Garceau, Simon P.

0000-0002-1043-8669

Mayo Clinic

Ottawa Hospital

Citations 2

Is the routine use of local antibiotics in the management of periprosthetic joint infections justified?
Gofton, Wade , Abdelbary, Hesham , Azad, Marisa , Grammatopoulos, George , Bourget-Murray, Jonathan , Azad, Marisa Ann , Garceau, Simon P.

HIP International | November 30, 2022 | Volume: 33 | Issue: 1 | Pages: 4-16

10.1177/11207000221139467 Get It

Periprosthetic joint infection (PJI) following total hip and total knee arthroplasty continues to be a leading cause of re-operation and revision arthroplasty. Not only is the treatment of PJI notoriously challenging, but success rates are variable. Regardless of the surgical strategy used, successful management of PJI requires a comprehensive surgical debridement focused at eradicating the underlying biofilm followed by appropriate antimicrobial therapy. Although systemic antimicrobial delivery continues to be a cornerstone in the treatment of PJI, many surgeons have started using local antibiotics to deliver higher concentrations of antibiotics directly into the vulnerable joint and adjacent soft tissues, which often have compromised vascularity. Available evidence on the use of topical powder, bone cement, and calcium sulphate carriers for local delivery of antibiotics during the initial treatment of PJI is limited to studies that are extremely heterogeneous. There is currently no level-1 evidence to support routinely using these products. Further, appropriately powered, prospective studies are needed to quantify the safety and efficacy of antibiotic-located calcium-sulphate carriers to justify their added costs. These products should not encourage surgeons to deviate from best practice guidelines, such as those recommended during the International Consensus Meeting on Musculoskeletal Infections.
Management of Periprosthetic Joint Infections After Hemiarthroplasty of the Hip
Bureau, Antoine, Azad, Marisa Ann , Abdelbary, Hesham , Azad, Marisa A, Azad, Marisa , Bourget-Murray, Jonathan , Grammatopoulos, George , Garceau, Simon P.

JBJS Reviews | September 26, 2022 | Volume: 10 | Issue: 9 | Pages: No page available

10.2106/jbjs.rvw.22.00020 Get It

» Periprosthetic joint infection (PJI) following hip hemiarthroplasty (HA) is a devastating complication, incurring immense health-care costs associated with its treatment and placing considerable burden on patients and their families. These patients often require multiple surgical procedures, extended hospitalization, and prolonged antimicrobial therapy. » Notable risk factors include older age, higher American Society of Anesthesiologists (ASA) score, inadequate antibiotic prophylaxis, non-antibiotic-loaded cementation of the femoral implant, longer duration of the surgical procedure, and postoperative drainage and hematoma. » Although the most frequent infecting organisms are gram-positive cocci such as Staphylococcus aureus , there is a higher proportion of patients with gram-negative and polymicrobial infections after hip HA compared with patients who underwent total hip arthroplasty. » Several surgical strategies exist. Regardless of the preferred surgical treatment, successful management of these infections requires a comprehensive surgical debridement focused on eradicating the biofilm followed by appropriate antibiotic therapy. » A multidisciplinary approach led by surgeons familiar with PJI treatment and infectious disease specialists is recommended for all cases of PJI after hip HA to increase the likelihood of treatment success.